← Back to Analyst Consensus 
LFST Buy
LifeStance Health Group, Inc.
Current Price —
Implied Upside —
Analysts 17
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 5, 2026 | Keybanc | maintain | Overweight → Overweight | — | 53% |
| Sep 10, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Sep 9, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Aug 19, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Aug 14, 2026 | JP Morgan | maintain | Neutral → Neutral | — | 54% |
| Aug 7, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Jul 24, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Jul 21, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Jul 14, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Jul 13, 2026 | Keybanc | maintain | Overweight → Overweight | — | 53% |
| Jun 5, 2026 | Goldman Sachs | initiate | Buy → Neutral | — | 54% |
| May 14, 2026 | JP Morgan | maintain | Neutral → Neutral | — | 54% |
| May 8, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Mar 6, 2026 | Barclays | maintain | Overweight → Overweight | $9 | 53% |
| Feb 26, 2026 | Canaccord Genuity | maintain | Buy → Buy | $10 | 48% |
| Feb 26, 2026 | UBS | maintain | Buy → Buy | $12 | 54% |
| Feb 26, 2026 | Keybanc | maintain | Overweight → Overweight | $9 | 53% |
| Feb 2, 2026 | BTIG | maintain | Buy → Buy | $11 | 52% |
| Dec 12, 2025 | BTIG | maintain | Buy → Buy | $10 | 52% |
| Dec 9, 2025 | Barclays | initiate | — → Overweight | $8 | 53% |
| Nov 13, 2025 | BMO Capital | initiate | — → Outperform | $8 | 53% |
| Nov 7, 2025 | UBS | maintain | Buy → Buy | $10 | 54% |
| Nov 6, 2025 | BTIG | maintain | Buy → Buy | $9 | 52% |
| Aug 8, 2025 | UBS | maintain | Buy → Buy | $9 | 54% |
| May 27, 2025 | UBS | upgrade | Neutral → Buy | $8.5 | 54% |
| Apr 8, 2025 | Keybanc | initiate | — → Overweight | $9 | 53% |
| Apr 3, 2025 | Canaccord Genuity | initiate | — → Buy | $8 | 48% |
| Dec 16, 2024 | Goldman Sachs | upgrade | Neutral → Buy | $10 | 54% |
| Nov 11, 2024 | Barclays | maintain | Underweight → Underweight | $7 | 53% |
| Aug 15, 2024 | UBS | maintain | Neutral → Neutral | $7.5 | 54% |
| Aug 9, 2024 | Barclays | maintain | Underweight → Underweight | $6 | 53% |
| Apr 22, 2024 | Morgan Stanley | reiterate | Overweight → Overweight | $10 | 54% |
| Mar 6, 2024 | Jefferies | maintain | Buy → Buy | $9 | 52% |
| Mar 4, 2024 | Goldman Sachs | maintain | Neutral → Neutral | $9 | 54% |
| Feb 29, 2024 | Barclays | maintain | Underweight → Underweight | $8 | 53% |
| Nov 22, 2023 | Goldman Sachs | maintain | Neutral → Neutral | $8 | 54% |
| Nov 17, 2023 | JP Morgan | maintain | Neutral → Neutral | $8 | 54% |
| Aug 10, 2023 | JP Morgan | maintain | Neutral → Neutral | $10 | 54% |
| Jul 13, 2023 | Morgan Stanley | reiterate | Overweight → Overweight | $10 | 54% |
| May 19, 2023 | Goldman Sachs | maintain | Neutral → Neutral | $9 | 54% |
| May 11, 2023 | Morgan Stanley | maintain | Overweight → Overweight | $10 | 54% |
| Jan 6, 2023 | Morgan Stanley | upgrade | Equal-Weight → Overweight | $8 | 54% |
| Nov 15, 2022 | Goldman Sachs | maintain | — → Neutral | $8 | 54% |
| Nov 14, 2022 | Cowen & Co. | maintain | — → Outperform | $8 | — |
| Aug 22, 2022 | Cowen & Co. | maintain | — → Outperform | $10 | — |
| May 10, 2022 | Morgan Stanley | maintain | — → Equal-Weight | $8 | 54% |
| Mar 21, 2022 | Goldman Sachs | maintain | — → Neutral | $10 | 54% |
| Mar 17, 2022 | UBS | downgrade | Buy → Neutral | $10 | 54% |
| Dec 17, 2021 | Morgan Stanley | maintain | — → Equal-Weight | $10 | 54% |
| Nov 9, 2021 | JP Morgan | downgrade | Overweight → Neutral | $12 | 54% |
Price Target Trend
May 7, 2026 Oct 26, 2026
EPS Estimates
0q —
0y —
+1y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days